Company: INV
Filing Date: 2025-04-29
Form Type: PRE 14A
Source: 0001628280-25-020657
Chunk: 63

Company: Innventure, Inc.
Filing Date: 2025-04-29
Form: PRE 14A
Chunk 63
---
 once payment is made and the applicable service requirements have lapsed. Mr. Haskell also earned a cash bonus of $2,500,000 in connection with the successful consummation of the Business Combination in 2024.

34

2024 Equity-Based Compensation In connection with the Business Combination, we adopted the Innventure, Inc. 2024 Equity and Incentive Compensation Plan (the “2024 Plan”). The 2024 Plan allows for equity compensation awards to our directors, employees and certain other service providers. In December 2024, the Compensation Committee approved equity incentive awards for the NEOs consisting of service-based RSUs and stock options under the 2024 Plan. Awards for our NEOs were as follows:

| NEO                                                                                                                        |     |    RSUs |     | Options* |
| Gregory Haskell.........................................................................................................   |     |       — |     |        — |
| Mike Otworth............................................................................................................   |     | 537,705 |     |  262,295 |
| Dr. John Scott............................................................................................................ |     | 336,066 |     |  163,934 |

_____________________________ * The options set forth in the table above were granted with an exercise price of $12.20, the closing stock price on the date of grant. In general, the options and RSUs granted to Mr. Otworth and Dr. Scott vest on October 2, 2025, or, if earlier, on the same date that the lock-up set forth in the contractual lock-up agreement entered into by such individual on October 24, 2023 terminates pursuant to its terms, subject to each NEO’s continuous service until the applicable vesting date. In December 2024, the Compensation Committee also approved a grant of 150,000 SARs (the “Accelsius SARs”) for each of Mr. Otworth and Dr. Scott. The Accelsius SARs each represent the right of the participant to receive a number of shares of Common Stock with a value equal to the appreciation in the value of a Class A Common Unit of Accelsius over a base price of $12.175. In general, the Accelsius SARs will be automatically exercised upon the earliest to occur of: (i) the 24-month anniversary of the grant date, (ii) the participant’s death, or (iii) the participant’s “disability” (as defined in the applicable award agreement). The Compensation Committee may, in its discretion, determine that the